AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. They aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Their clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and they also are advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, a foundation designed to scale gene therapy worldwide.
| Headquarters | Cambridge, MA with an office in Toronto, ON |
| Website | www.avrobio.com |
| Pipeline | Phase 2 |
| Partners | Center for Commercialization of Regenerative Medicine (CCRM) |
| @avrobio |